SWG Educational Activities
EHA-SWG meetings
An EMSCO meeting was held in October 2023 (Nice, France). This involved two days of intense discussions on:
- The science of MDS
- Current and future trials
The SWG meeting was embedded, with a specific focus on designing clinical trials.
Presentations at national and international meetings
Contributions to EHA2023
- S102 LUSPATERCEPT VERSUS EPOETIN ALFA FOR TREATMENT (TX) OF ANEMIA IN ESA-NAIVE LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) PATIENTS (PTS) REQUIRING RBC TRANSFUSIONS: DATA FROM THE PHASE 3 COMMANDS STUDY
Matteo Giovanni Della Porta et al. - S164 DISEASE MODIFYING ACTIVITY OF IMETELSTAT IN PATIENTS WITH HEAVILY TRANSFUSED NON-DEL(5Q) LOWER-RISK MYELODYSPLASTIC SYNDROMES RELAPSED/REFRACTORY TO ERYTHROPOIESIS STIMULATING AGENTS IN IMERGE PHASE 3
Valeria Santini et al. - S165 CONTINUOUS TRANFUSION INDEPENDENCE WITH IMETELSTAT IN HEAVILY TRANSFUSED NON-DEL(5Q) LOWER-RISK MYELODYSPLASTIC SYNDROMES RELAPSED/REFRACTORY TO ERYTHROPOIESIS STIMULATING AGENTS IN IMERGE PHASE 3
Uwe Platzbecker et al. - S170 MYELODYSPLASTIC NEOPLASMS (MDS) CLASSIFICATION FROM WHO 2017 TO WHO 2022 AND ICC 2022): AN EXPANDED ANALYSIS OF 7017 PATIENTS ON BEHALF OF THE INTERNATIONAL CONSORTIUM FOR MDS (ICMDS)
Rami S. Komrokji et al. - S173 RETROSPECTIVE STUDY OF LENALIDOMIDE DISCONTINUATION IN PATIENTS WITH MYELODYSPLASTIC SYNDROME HARBORING DEL(5Q). A HARMONY ALLIANCE STUDY
Elena Crisà et al. - P693 LUSPATERCEPT RESTORES EFFECTIVE ERYTHROPOIESIS AND PROVIDES SUPERIOR AND SUSTAINED CLINICAL BENEFIT VS EPOETIN ALFA: BIOMARKER ANALYSIS FROM THE PHASE 3 COMMANDS STUDY
Uwe Platzbecker et al. - P697 DISTINCT SPLICING ALTERATIONS ASSOCIATED WITH CLINICAL RESPONSE TO LUSPATERCEPT IN PATIENTS WITH LOWER‑RISK MYELODYSPLASTIC SYNDROMES FROM THE MEDALIST STUDY
Srinivas Aluri et al. - P705 AZACYTIDINE THERAPY REVERTS MDS-ASSOCIATED CHANGES IN MSC-DERIVED EXTRACELLULAR MATRIX
Amanpreet Bains et al. - P731 SURVIVAL IN LOWER-RISK MDS PATIENTS FROM EUMDS REGISTRY BY TWO TRANSPLANT SELECTION CRITERIA - IMPLICATIONS FOR TRANSPLANT DECISION
Aleksandar Savic et al. - P732 ANALYSIS OF PATIENT-REPORTED FATIGUE IN IMERGE PH3 TRIAL OF IMETELSTAT VS PLACEBO IN HEAVILY TRANSFUSED NON-DEL(5Q) LOWER-RISK MYELODYSPLASTIC SYNDROMES R/R TO ERYTHROPOIESIS STIMULATING AGENTS
Mikkael Sekeres et al. - PB2014 A PHASE 2/3 TRIAL OF ORAL AZACITIDINE IN PATIENTS WITH LOW- OR INTERMEDIATE-RISK MYELODYSPLASTIC SYNDROMES
Guillermo Garcia-Manero et al. - PB2670 EQOL-MDS TRIAL: PATIENT-REPORTED OUTCOMES IN PATIENTS WITH LOWER RISK MYELODYSPLASTIC SYNDROMES WITH SEVERE THROMBOCYTOPENIA
Esther Oliva et al.
Contributions to ASH 2023
- 122 Clinical Text Reports to Stratify Patients Affected with Myeloid Neoplasms Using Natural Language Processing
Gianluca Asti et al. - 193 Efficacy and Safety of Luspatercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent (ESA)-Naive Patients (Pts) with Transfusion-Dependent (TD) Lower-Risk Myelodysplastic Syndromes (LR-MDS): Full Analysis of the COMMANDS Trial
Guillermo Garcia-Manero et al. - 194 Efficacy of Imetelstat in Achieving Red Blood Cell Transfusion Independence (RBC-TI) across Different Risk Subgroups in Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis-Stimulating Agents (ESAs) in IMerge Phase 3 Study
Rami S. Komrokji et al. - 195 Efficacy and Safety of Roxadustat for Treatment of Anemia in Patients with Lower-Risk Myelodysplastic Syndrome (LR-MDS) with Low Red Blood Cell (RBC) Transfusion Burden: Results of Phase III Matterhorn Study
Moshe Mittelman et al. - 197 Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Myelodysplastic Syndromes (MDS)
Cristina Astrid Tentori et al. - 319 Efficacy and Safety of Venetoclax in Combination with Azacitidine for the Treatment of Patients with Treatment-Naive, Higher-Risk Myelodysplastic Syndromes
Jacqueline S. Garcia et al. - 915 Long-Term Evaluation of Luspatercept in Erythropoiesis‑Stimulating Agent (ESA)-Intolerant/Refractory Patients (pts) with Lower-Risk Myelodysplastic Syndromes (LR-MDS) in the Phase 3 MEDALIST Study
Valeria Santini et al. - 997 Molecular Taxonomy of Myelodysplastic Syndromes and Its Clinical Implications
Elsa Bernard et al. - 998 Data-Driven Harmonization of 2022 Who and ICC Classifications of Myelodysplastic Syndromes/Neoplasms (MDS): A Study By the International Consortium for MDS (icMDS)
Luca Lanino et al. - 1001 TP53 Gene allelic State in Myelodysplastic Syndromes (MDS) with Isolated 5q Deletion
Julia Montoro et al. - 3236 Molecular Measurable Residual Disease (MRD) Clearance (≤1%) Is Associated with Improved Clinical Outcomes in Patients with Higher-Risk Myelodysplastic Neoplasms (HR-MDS): An Exploratory Analysis of Stimulus-MDS1 in Patients Receiving Sabatolimab or Placebo + Hypomethylating Agent (HMA)
Amer M. Zeidan et al. - 3251 FORTITUDE: A Phase 2 Open-Label Study in Progress to Evaluate Etavopivat for the Treatment of Anemia in Patients with Lower-Risk Myelodysplastic Syndromes
Mikkael A. Sekeres et al. - 4591 Impact of Genomic Landscape and Mutational Burden on Primary Endpoint Responses in the COMMANDS Study
Rami S. Komrokji et al. - 4595 Impact of Mutational Burden and IPSS-M on Response to ESAs in Lower Risk Myelodysplastic Neoplasms
Marco Gabriele Raddi et al. - 4596 Patient-Reported Outcomes (PRO) of Luspatercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent (ESA)-Naïve, Transfusion-Dependent (TD), Lower-Risk Myelodysplastic Syndromes (LR-MDS): Results from the Phase 3 COMMANDS Study
Esther Natalie Oliva et al. - 4605 Durable Continuous Transfusion Independence (TI) with Imetelstat in IMerge Phase 3 for Patients with Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Syndromes (LR-MDS) Relapsed/Refractory (R/R) to or Ineligible for Erythropoiesis-Stimulating Agents (ESAs)
Uwe Platzbecker et al.
Collaborations on international projects
Continued involvement in HARMONY and EuroBloodNet EU initiatives.
Several common clinical trials in conduct and planning phase (in both LR and HR MDS), partly involving translational programs.
Currently ongoing collaborative trials in MDS:
- LUSPLUS trial (NCT05181592)
- LENNON trial (NCT05384691)
- LUCAS trial (NCT05178342)
- CANFIRE trial (NCT05237713)
- IMpress trial (NCT05583552)
- PALOMA trial (NCT04061239)
Other activities
- Several SWG members have acted as reviewers for the EHA congresses.
- Individual study group meetings, MDS workshops etc. on country level.
- Country-level patient days.
Back